The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 16.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (31 analysts) rates it buy, with a mean price target of $302.
NXP Semiconductors
NXPI · a US exchange · USD · Market cap $56.5B · 32,169 employees
NXP Semiconductors N.V.
FAIL · Does not pass the screenAt the last full screen
2026-09-08
Screened 2026-09-08 · the tape above runs as of 23:00 UTC · 17 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
This name holds its markdown label.
NXP Semiconductors holds its Markdown at $223.87. Consolidating, no directional conviction, held for 18 days.
| Phase | Markdown · caution |
| Quantitative state | Consolidating, no directional conviction, held for 18 days |
| Price at the screen | $223.87 |
| Valuation | 19.12 trailing · 12.37 forward price to earnings |
| Values screen | FAIL · score 10.0 |
| Beta | 1.82 |
Five Screens, Shown in Full
Does not pass. Debt ratio
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 46.02% | Below 33% | Interest-bearing debt is 46.0% of its assets, above the one-third ceiling the screen allows. | Fail |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 14.91% | Below 49% | Money owed to the company is 14.9% of assets, under the 49% limit. | Pass |
| Revenue purity | 1.18% | Below 5% | Only 1.2% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is WorthThe Fair Value Range
Our framework reads AVOID: it trades at roughly a 3% discount to our $231.45 fair value, strong competitive moat, 19.50% revenue growth.
Fair value range in USD, drawn from the 2026-09-08 screen. The gold marker is the market price at the same screen. A 3.4% margin of safety to the base estimate.
Third-party analyst targets: 29 covering, consensus None. The average target sits +38% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-08 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsChipmaker looks cheap but hides cyclical traps
Every phone, car and factory machine needs chips, yet NXP trades at a forward multiple of 14.9 times earnings with revenue growth of 12 percent and a 21 percent profit margin. The business carries a strong moat and 26 percent ROE, yet our fair value sits 14 percent below the current price of 266 dollars, so we pass. The ethical screen also flags excessive debt, ruling the name out regardless of analyst targets near 310 dollars.
This is a classic cyclical value trap. Peak cycle earnings often flatter the multiple and mask the sharp drops that follow when auto and industrial demand turns. Strong returns on equity can vanish quickly once volumes fall, leaving investors holding inventory and capacity that suddenly looks expensive.
Analysis, not advice.
| Forward P/E | 12.4xcheap for a company growing this fast |
| Trailing P/E | 19.1xreasonably valued |
| EPS, trailing | 11.71 |
| EPS, forward | 18.10 |
| Revenue growth | +19.5%steady growth |
| Profit margin | 22.6%healthy profit margins |
| Return on equity | 27.9%an exceptional return on shareholder capital |
| FCF yield | 6.30% |
| Dividend yield | 138.00% |
| Debt to equity | 0.93moderate, manageable leverage |
| Current ratio | 2.04comfortably covers its short-term bills |
| Beta | 1.82much more volatile than the market |
| Short interest, float | 0.04% |
| 52-week range | 183.00 - 339.95 |
| Moat | STRONG |
| Market cap | $56.5B |
| Employees | 32,169 |
The risks · The things to watch: it already moves more than the market on an average day; its business and earnings are exposed to Netherlands and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeNXPI trades on a US exchange (the company is based in Netherlands). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (31 analysts) rates it buy, with a mean price target of $302. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (31 analysts) rates it buy, with a mean price target of $302. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (31 analysts) rates it buy, with a mean price target of $302. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (31 analysts) rates it buy, with a mean price target of $302. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (31 analysts) rates it buy, with a mean price target of $302. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (31 analysts) rates it buy, with a mean price target of $302. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (31 analysts) rates it buy, with a mean price target of $302. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 9.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (31 analysts) rates it buy, with a mean price target of $302. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (31 analysts) rates it buy, with a mean price target of $302.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- NXP Semiconductors and Broadcom Shares Plummet, What You Need To Know StockStory · 16 Jul 2026
- NXP Semiconductors (NXPI) Falls With Chip Selloff, Is It Still 8% Undervalued? Simply Wall St. · 16 Jul 2026
- How Investors May Respond To NXP Semiconductors (NXPI) Sector-Wide Profit Taking And Geopolitical Tensions Simply Wall St. · 15 Jul 2026
- Texas Instruments' CapEx Moderates: Can Cash Flow Improve Further? Zacks · 15 Jul 2026
- NXP Semiconductors (NXPI) Stock Looks Fair On Cash Flow Yet Cheap On Earnings Simply Wall St. · 15 Jul 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-30 | HARDY ANDREW | Officer | 4,880 | · | |
| 2026-04-29 | SOTOMAYOR RAFAEL | Chief Executive Officer | 1,095 | · | |
| 2026-04-23 | JENSEN CHRISTOPHER L | Officer | 4,576 | $1,070,921 | |
| 2026-04-23 | HARDY ANDREW | Officer | 5,289 | $1,242,915 | |
| 2026-03-16 | MICALLEF ANDREW JOSEPH | Chief Operating Officer | 1,000 | $194,580 | |
| 2026-02-04 | HARDY ANDREW | Officer | 823 | · | |
| 2026-01-02 | WUAMETT JENNIFER B. | General Counsel | 12,425 | $2,745,218 | |
| 2025-12-15 | MICALLEF ANDREW JOSEPH | Chief Operating Officer | 1,000 | $230,780 | |
| 2025-12-03 | SOUTHERN JULIE | Chairman of the Board | 225 | $50,733 | |
| 2025-12-03 | JENSEN CHRISTOPHER L | Officer | 2,300 | $524,791 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 1 May2026 | Ro Khanna | Democrat | buy | 1K–15K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $305.99 | -6.3% | · | $937 | -6.3% |
| 2 months | $204.37 | +40.4% | · | $1,404 | +40.4% |
| 3 months | $190.23 | +50.8% | $1.01 | $1,513 | +51.3% |
| 6 months | $230.63 | +24.4% | $1.01 | $1,248 | +24.8% |
| 1 year | $214.63 | +33.6% | $4.06 | $1,355 | +35.5% |
| 2 years | $266.97 | +7.4% | $8.11 | $1,105 | +10.5% |
| 3 years | $174.99 | +63.9% | $12.17 | $1,709 | +70.9% |
| 5 years | $183.92 | +56.0% | $18.25 | $1,659 | +65.9% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever NXPI does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.